Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | MAOB | P27338 | 4/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | BCHE | P06276 | 1/20 | 0.60 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.58 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339813 | 0.89 | LMNA (0.82) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL2089434 | 0.85 | LMNA (0.64) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| Benzylphenylether SCHEMBL22499954 | 0.84 | LMNA (0.68) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL10609652 | 0.84 | LMNA (0.75) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| Benzylphenylether SCHEMBL61660 | 0.84 | LMNA (0.74) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL2093453 | 0.83 | LMNA (0.67) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL94338 | 0.83 | LMNA (0.67) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL5538712 | 0.82 | LMNA (0.72) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL9808056 | 0.82 | LMNA (0.72) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL197017 | 0.82 | LMNA (0.72) | LMNACYP1A2PTGS1SLC6A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4181733-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1980-01-01 | — | — | US | claimed |
| CN-101516826-B | Beta-3 receptor ligands | UNIV BARI | 2015-03-04 | — | — | CN | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-5723489-A | ADRENERGIC BLOCKING AGENTS OR STIMULANTS FOR GASTROINTESTINAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-03-03 | — | — | US | disclosed |
| CN-1161690-A | Substituted pyridines, their use as pesticides and fungicides | HOECHST SCHERING AGREVO GMBH (DE) | 1997-10-08 | — | — | CN | disclosed |
| US-5021566-A | Carbapenicillins; preservatives; antiseptics; grampositive and gram negative bacteria | MERCK & CO. INC. (US) | 1991-06-04 | — | — | US | disclosed |
| US-4181733-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1980-01-01 | — | — | US | disclosed |
| US-4172144-A | Schiff's base derivatives of thienamycin | MERCK & CO., INC. (US) | 1979-10-23 | — | — | US | disclosed |
| US-4150145-A | ANTIBIOTIC, BACTERICIDES | MERCK & CO., INC. (US) | 1979-04-17 | — | — | US | disclosed |
| US-4150156-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1979-04-17 | — | — | US | disclosed |
| EP-0001264-A1 | Substituted N-methylene derivatives of thienamycin sulfoxide and sulfone and their preparation | MERCK & CO. INC. (US) | 1979-04-04 | — | — | EP | disclosed |
| EP-0001265-A1 | O-, N- and carboxyl derivatives of thienamycin sulfoxide and sulfone, their preparation and pharmaceuticals containing said compounds | MERCK & CO. INC. (US) | 1979-04-04 | — | — | EP | disclosed |
| US-4123528-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1978-10-31 | — | — | US | disclosed |
| US-4078067-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4078068-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4076826-A | ANTIBIOTIC | MERCK & CO., INC. (US) | 1978-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | LMNA 4594/4885CYP1A2 420/4885PTGS1 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.